AHZ – AGM 16 November 2017 (Webinar)
Thurday 16th November, Admedus held the 2017 Annual General Meeting – please view the investor presentation below. AHZ – AGM 16 November 2017
November 17th 2017Find out more
Admedus announces facility agreement with Partners for Growth
Admedus Ltd today announced that it has entered into an agreement with Partners for Growth (PFG) for a secured debt facility of up to AUD $10 million. Based in the San Francisco Bay area, PFG is a partnership that provides capital funding debt solutions to private and public technology and life science companies. Read full […]
October 26th 2017Find out more
Admedus TAVR project on track with new IP applications
Admedus Ltd today announced that it has submitted IP applications relating to the development of a new Transcatheter Aortic Valve Replacement (TAVR) device. Read the full ASX statement here.
October 24th 2017Find out more
New neck and head cancer treatment a step closer to trials
As reported widely across Australian media outlets, Admedus Immunotherapies recently received a $250,000 Government grant from the Advance Queensland Ignite Ideas Fund to support human clinical trials, led by Professor Ian Frazer, of a new vaccine that could be used to treat head and neck cancer. Find a copy of the story on News.com, 7 News or Brisbane Times. Read the full […]
October 23rd 2017Find out more
Notice of 2017 Annual General Meeting
Admedus is pleased to announce the Annual General Meeting will be held at 11.00am (AEST) on 16 November 2017, at the Novotel Hotel in Brisbane, Australia.
October 13th 2017Find out more
Admedus is a global healthcare company that develops, commercialises and distributes next generation medical technologies and devices. Our mission is to provide patients around the world with a better quality of life through access to our leading medical solutions and products.Learn More